(NASDAQ: PCVX) Vaxcyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.6%.
Vaxcyte's earnings in 2025 is -$657,201,000.On average, 12 Wall Street analysts forecast PCVX's earnings for 2025 to be -$735,889,557, with the lowest PCVX earnings forecast at -$815,912,556, and the highest PCVX earnings forecast at -$688,632,397. On average, 12 Wall Street analysts forecast PCVX's earnings for 2026 to be -$818,203,416, with the lowest PCVX earnings forecast at -$1,078,903,238, and the highest PCVX earnings forecast at -$571,798,557.
In 2027, PCVX is forecast to generate -$875,723,628 in earnings, with the lowest earnings forecast at -$957,029,508 and the highest earnings forecast at -$787,597,531.